Auditing the safety and efficacy of interventional septal reduction therapies in hypertrophic obstructive cardiomyopathy at a specialized tertiary centre

FUNDING ACKNOWLEDGEMENTS: Type of funding sources: None. BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a recognized cause of sudden cardiac death and dysrhythmias. Patients with HCM and marked left ventricular outflow tract obstruction (LVOTO) may benefit from invasive therapies such as septal my...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorbini, M, Savvatis, K, Guttmann, O, Omahony, C, Shipolini, A, Yates, M, Rathwell, C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
25.99 - Congenital Heart Disease and Paediatric Cardiology, Other
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207059/
http://dx.doi.org/10.1093/europace/euad122.515

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207059/
http://dx.doi.org/10.1093/europace/euad122.515

Ejemplares similares